Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: A Polyarteritis Nodosa Conundrum

Hannah Krebsbach, MD, Ileannette Robledo Vega, MD, Nirupa Patel, MD, & Nkechinyere Emejuaiwe, MD, MPH  |  Issue: March 2022  |  March 14, 2022

Figure 1: Lower Extremity Ulceration

Figure 1: Lower Extremity Ulceration

Varying stages of ulceration are seen on the left (L) and right (R) lower extremities. An eschar formation is on the left (red arrow), and a superficial ulceration is on the right (black arrow).

Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries. The clinical subsets of PAN are idiopathic, generalized, secondary hepatitis B virus (HBV) associated and cutaneous PAN. These clinical subsets are important because of their therapeutic implications.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Virtually any organ system can be affected in generalized PAN, but this vasculitis tends to spare the lungs.1 Pleural effusion, transient infiltrates and bronchial artery vasculitis are uncommon manifestations that have been reported in association with PAN.2 These pulmonary manifestations tend to be a reflection of renal or cardiac insufficiency rather than a direct result of the necrotizing vasculitis.

In the case below, we report on the unusual occurrence of shrinking lung syndrome (SLS) and brachial plexopathy in a confirmed case of PAN. This case highlights a broader consideration for the etiology of dyspnea in PAN and adds to the list of immune-mediated diseases associated with SLS and Parsonage-Turner syndrome (PTS).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Case Presentation

A 51-year-old man presented to the hospital with a four-month history of recurrent, bilateral, lower extremity edema and ulcerations that had been treated with intermittent courses of corticosteroids. The ulcers recurred whenever the cortico­steroids were tapered. The patient had experienced fever, dyspnea, orchitis, postprandial abdominal pain, uncontrolled hypertension and intermittent right arm pain during the course of his illness. Just prior to hospitalization he had developed dyspnea. His examination was otherwise unremarkable.

The patient’s past medical history was significant for type 2 diabetes mellitus, hypertension and coronary artery disease. His family history was notable for Sjögren’s syndrome and systemic lupus erythematous (SLE). He had a history of smoking tobacco, but denied alcohol or illicit drug use.

On our initial physical examination, the patient had normal vital signs. Despite his complaints of dyspnea and orthopnea, he had normal pulmonary and cardiac examinations. The muscle strength in his right upper arm was 3/5, and he had pitting edema on his lower extremities.

The examination of the patient’s skin was notable for livedo reticularis and ulceration of the lower extremities, extending from the calves to the heels of his feet (see Figure 1, above). The ulcers were of varying stages, with some being early stage and superficial, and other lesions deep with eschar formation.

Laboratory analysis is listed in Table 1.

Table 1: Laboratory Test Results

LaboratoryTest Result*Reference Range
White cell count11.6 K/uL4.8–10.8 K/uL
Serum eosinophil %0.0360.0–6.1%
Serum eosinophil (number)0.4 K/uL0.0–0.4 K/uL
Hemoglobin12.4 g/dL14–18 g/dL
Platelet385 K/uL140–420 K/uL
Serum creatinine0.9 mg/dL0.6–1.3 mg/dL
Aspartate aminotransferase (AST)21 IU/L15–41 IU/L
Alanine aminotransferase (ALT)35 IU/L12–63 IU/L
Creatine phosphokinase (CPK)110 IU/L25–250 IU/L
C-reactive protein1.63 mg/dL0–0.6 mg/dL
Erythrocyte sedimentation rate62 MM/HR0–15 MM/HR
Anti-nuclear antibody (ANA)1:640 titer (nucleolar)<1:80 titer
Anti-proteinase 3 (anti-PR3)<3.5 U/mL0.0–3.5 U/mL
Anti-myeloperoxidase (anti-MPO)<9.0 U/mL0.0–9.0 U/mL
Anti-double-stranded DNA (anti-dsDNA)NegativeNegative
Interleukin-62.4 pg/mL0.0–15.5 pg/mL
Interleukin-2<31.2 pg/mL0.0–31.2 pg/mL
IgE, Total779 IU/mL6–495 IU/mL
C3 complement117.0 mg/dL90–180 mg/dL
C4 complement28.0 mg/dL10–40 mg/dL
Hepatitis B surface antigenNonreactiveNegative
Hepatitis C antibodyNonreactiveNonreactive
HIV screen (AB/AG combo)NonreactiveNonreactive
B-type natriuretic peptide12 pg/mL0–100 pg/mL
Urine bloodNegativeNegative
Urine proteinNegativeNegative
*abnormal findings indicated in bold

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:case reportdyspneaFellowsFellows Forumpolyarteritis nodosashrinking lung syndrome

Related Articles

    Case Report: Diagnosing, Treating Hepatitis B-Linked Polyarteritis Nodosa

    September 17, 2019

    Hepatitis B virus (HBV) associated polyarteritis nodosa (PAN) is an increasingly rare vasculitis in developed countries due to advances in HBV vaccination and antiviral therapy. However, the condition does persist, and rheumatologists should consider it when evaluating vasculitis cases. Below, we discuss a case that illustrates the varied clinical presentations PAN can encompass. A high…

    Vasculitis Guidelines in Focus, Part 4: Polyarteritis Nodosa

    September 22, 2021

    Jason Springer, MD, MS, served as one of the lead authors of the ACR/VF guidelines for polyarteritis nodosa (PAN), and talks about the recommendations specific to PAN here.

    A Case of Nodular Rash & Painful Joints

    October 10, 2022

    Polyarteritis nodosa (PAN) is a necrotizing vasculitis, predominantly involving medium-sized arteries, that causes systemic disease, and, less commonly, cutaneous-limited disease. The population prevalence for PAN ranges from 2 to 33 per million.1-3 Estimates vary due to the increased recognition and classification of other forms of vasculitides over time and variation in the regional prevalence of…

    Labored Breathing

    January 1, 2007

    Strategies to diagnose and manage dyspnea in the scleroderma patient

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences